Home › Drug Product Listings › Insulin aspart + niacinamide

Insulin aspart + niacinamide

Trade Name: 
Fiasp
Manufacturer/Distributor: 
Novo Nordisk Canada
www.novonordisk.ca
1-800-465-4334
Classification: 
Insulin analogue
ATC Class: 
A10AB - insulin analgoues for injection, fast-acting
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2017/02/02
Date Marketed in Canada (yyyy/mm/dd): 
2017/04/06
Presentation: 
Injection: 100 IU/mL. DIN: 02460408 - 10 mL vial
Injection: 100 IU/mL. DIN: 02460416 - 3 mL penfill cartridge
Injection: 100 IU/mL. DIN: 02460424 - 3 mL pre-filled pwn
Comments: 
Fiasp contains insulin aspart as well as niaciniamide (vitamin B3) which results in a faster initial absorption of insuin, leading to an earlier onset and and greater early insulin exposure. The onset of action is about five minutes earlier with Fiasp than with NovoRapid (insulin aspart) and the peak effect occurs approximately 11 minutes earlier. Therefore, if hypoglycemia occurs, it may occur earlier after an injection of Fiasp compared with other mealtime insulins.
Source: 
Canadian Healthcare Network 06 April 2017
Back to: 
Drug Product Listings
  • Share this
  • Printer-friendly version
  • PDF version